Agilent Technologies Inc. (NYSE: A) announced that Professor Isabelle Plante at Institut National de la Recherche Scientifique (INRS), and&n...
Headway, the company building a new mental healthcare system, announced its participation in the Aligned Innovation initiative, a groundbreaking cross-indu...
At the American Society of Human Genetics (ASHG) Annual Meeting (Nov. 5-9, 2024), Complete Genomics, a pioneering genomic sequencing company, will highligh...
BioCity Biopharma (BioCity) announced late-breaking results of the 2-SUCCEED clinical trial of SC0062, a selective endothelin receptor type A (ETA) an...
OmniActive Health Technologies (OmniActive) announced the acquisition of ENovate Biolife (ENovate), further strengthening its commitment to innovative...
Theriva™ Biologics (NYSE American: TOVX), a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer and relate...
Medtronic plc (NYSE: MDT), a global leader in healthcare technology, announced that the Centers for Medicare & Medicaid Services (CMS) has granted...
Pangea Laboratory has partnered with Unilabs, a leading European provider of clinical laboratory testing and diagnostic imaging services, to bring the Blad...
Abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates announced a significant expansion in their quality control (QC) test...
Biogen Inc. (Nasdaq: BIIB) and Neomorph Inc. announced a research collaboration to discover and develop molecular glue degraders for priority ta...
Novartis announced that Scemblix® (asciminib) was granted accelerated approval by the US Food and Drug Administration (FDA) for adult patients wit...
Merck, a leading science and technology company, announced a € 70 million expansion of its ADC manufacturing capabilities and capacity at its Bioconju...
Biogen Inc. (Nasdaq: BIIB) announced upcoming data presentations and programming at the Clinical Trials on Alzheimer’s Disease (CTAD) annual con...
GSK plc (LSE/NYSE: GSK) announced new preliminary data for Arexvy (respiratory syncytial virus vaccine, recombinant adjuvanted) in adults aged 18-49 at inc...
© 2025 Biopharma Boardroom. All Rights Reserved.
